International Conferences

Recommended Conferences for Sports

Sports

---

<b> Cancer Bioengineering</b><br><br>

As per available reports about 57 <a href="<http://www.omicsonline.org/scientific-journals.php"> relevant journals </a>, 21<a href=" <http://www.omicsgroup.com/"> Conferences </a> 705 workshops are presently dedicated exclusively to cancer biology about 2455 articles are being published on cancer biology<br/><br/>

Cancer is a disease of misregulated genes, proteins, metabolites, cells, and biophysical forces.  Early-stage cancers are difficult to diagnose and characterize, and late-stage cancers are invariably hard to treat.  Clinically, cancer is an enormous burden on human health and society.  The challenges span multiple spatiotemporal scales and will require engineering approaches to solve. Multi-pronged effort aimed at cancer biology, cancer imaging, and cancer therapy.  Tissue foci include cancers of the breast, brain, pancreas, lung, and kidney. <br/><br/>
 

<a href="<http://www.conferenceseries.com/"> OMICS International </a>Organizes 1000+ <a href="<http://www.conferenceseries.com/"> Global Events </a> Every Year across USA, Europe & Asia with support from 1000 more <a href="<http://www.omicsonline.org/international-societies-world-fedarations-scientific-associations.php "> scientific societies </a> and Publishes 700+ <a href="<http://www.omicsonline.org/open-access-journals-list.php/"> Open access journals </a> which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The <a href="<http://www.conferenceseries.com/"> conference series </a> website will provide you list and details about the conference organize worldwide. <br/><br/>

<b>Scope and Importance: </b><br><br>

The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumor, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by nonmalignant cells. Effective cancer-targeting therapies will require both passive- and active-targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Designing a targeted therapy includes the selection and optimization of a nanoparticle delivery vehicle for passive accumulation in tumors, a targeting moiety for active receptor-mediated uptake, and stimuli-responsive polymers for control of drug release. The future direction of cancer targeting is a combinatorial approach, in which targeting therapies are designed to use multiple-targeting strategies. The combinatorial approach will enable combination therapy for delivery of multiple drugs and dual ligand targeting to improve targeting specificity. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes.<br/><br/>
 

<b>Market Analysis: </b><br><br>

Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. Metastases are the major cause of death from cancer. Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012.

About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favorable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.<br/><br/>

 

<b>:Conferences </b>:<br/><br/>

 

·         <a href=" http://cancer.global-summit.com/america/"> 6^th World Congress on

Cancer Therapy, USA</a><br/>

·         <a href=" http://cancer.global-summit.com/america/"> 7^th  Global Summit on

Cancer Therapy, Dubai, UAE</a><br/>

·         <a href=" http://cancer.global-summit.com/europe/"> 8^th Euro Global Summit on

Cancer Therapy, Valencia, Spain</a><br/>

·         <a href=" http://cancer.global-summit.com/india/"> 9^th Indo Global Summit on Cancer Therapy, Hyderabad, India</a><br/>

·         <a href=" http://cancer.global-summit.com/asia-pacific/"> 11th Asia-Pacific Oncologists Annual Meeting</a><br/>

·         <a href=" http://integrativebiology.conferenceseries.com/"> Integrative Biology-2016, Berlin, Germany </a><br/>

·         <a href=" http://syntheticbiology.conferenceseries.com/"> Synthetic Biology Conference , USA</a><br/>

<b> Relevant Organization and Associations </b>:<br/><br/>

European Society for Medical Oncology</br>

European Society of Gynaecological Oncology</br>

EuroPharm Forum</br>

Friends of Cancer Research) </br>

American Cancer Society</br>

National Cancer Institute</br>

German Cancer Aid</br>

Cancer Council Australia</br>

Edinburgh Cancer Research Centre</br>

World Cancer Research Fund, UK</br> and many more

<b>:Company list<b>: </br></br>

Roche</br>

Novartis</br>

Celgene</br>

Bristol-Myers Squibb </br>

Lilly </br>

Takeda </br>

Merck & Co. </br>

AstraZeneca </br>

Pfizer </br>

Pharmacyclics </br>

This page will be updated regularly.

This page was last updated on April 26, 2024